| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| C3011 | Human CLDN18.2 CHO-K1 Stable Cell Line | 2 vials | $6000 | Order |
| Catalog Number | C3011 |
|---|---|
| Cell Line Name | Human CLDN 18.2 CHO-K1 Stable Cell Line |
| Accession Number | NP_001001026 (Met1-Val261) |
| Host Cell | CHO-K1 (Adherent cells) |
| Quantity | Two vials of frozen cells (~1x106 per vial) |
| Culture Medium | DMEM with 10% FBS and 4 µg/ml puromycin |
| Freezing Medium | 90% FBS and 10% DMSO |
| Storage | Liquid nitrogen |
| Product Datasheet: | Download PDF |
Detection of human CLDN18.2 expression on human CLDN18.2-CHO Stable cells using an anti-CLDN18.2 mAb (Accurus, Cat. #A1008), followed by staining with a PE-anti-human IgG antibody.
Claudin-18 (CLDN18) is a member of a large family of four-span transmembrane proteins called Claudins. These proteins are the essential components of the mammalian tight junctions (TJs) in epithelial cells. Claudin-18 has two splice variants, 18.1 and 18.2. While CLDN18.1 is specifically expressed in the lung tissue, CLDN18.2 expression in normal tissue is more restricted and is only detected in small patches of stomach mucosal. CLDN18.2 expression is elevated in many types of epithelial cancers including stomach, esophagus, pancreatic and ovarian cancers. The expression of CLDN18.2 is not only detected in primary tumors, but also in the metastatic sites. Therefore, CLDN18.2 is an ideal target for monoclonal antibody-based cancer therapies.
Türeci O. et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene, 481:83-92. 2011
Sahin U. et al. Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. Clin. Cancer Res. 14:7624-7634. 2008.
Niimi T. et al. Claudin-18, a Novel Downstream Target Gene for the T/EBP/NKX2.1 Homeodomain Transcription Factor, Encodes Lung- and Stomach-Specific Isoforms through Alternative Splicing. Mol. Cell. Biol. 21:7380-7390. 2001